All tenders
75A50124C00054
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
Office of Assistant Secretary for Preparedness and Response · United States
This tender closed on Thursday, December 31, 2026. Browse open opportunities
Time Left to Bid
Closed
ClosedOtherFederal
Basic information
- Reference number
- 75A50124C00054
- Issuing organization
- Office of Assistant Secretary for Preparedness and Response · Find award history →
- Government level
- Federal
- Solicitation type
- Other
- Title
- THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
- Source
- USASpending (Federal)
- Source ID
- usa-75A50124C00054
Details
- Location
- United States
Description
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN Awarded to: AURAVAX THERAPEUTICS, INC. Agency: Department of Health and Human Services Sub-agency: Office of Assistant Secretary for Preparedness and Response Award type: DEFINITIVE CONTRACT
Dates
- Publication
- 2024/09/23 12:00:00 AM UTC
- Closing date
- 2026/12/31 12:00:00 AM UTC
Estimated value
$750K USD
Classification
Normalized category
Other